Published in Cell Death Dis on March 13, 2014
URI expression in cervical cancer cells is associated with higher invasion capacity and resistance to cisplatin. Am J Cancer Res (2015) 0.83
URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro. Am J Cancer Res (2016) 0.75
URI prevents potassium dichromate-induced oxidative stress and cell death in gastric cancer cells. Am J Transl Res (2016) 0.75
Colorectal cancer cells display chaperone dependency for the unconventional prefoldin URI1. Oncotarget (2016) 0.75
Melatonin improves age-induced fertility decline and attenuates ovarian mitochondrial oxidative stress in mice. Sci Rep (2016) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res (2005) 5.87
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
The proteasome: a suitable antineoplastic target. Nat Rev Cancer (2004) 5.22
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A (1987) 3.92
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Interleukin 6 and its receptor: ten years later. Int Rev Immunol (1998) 2.96
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood (2003) 2.82
SP analysis may be used to identify cancer stem cell populations. Exp Cell Res (2006) 2.49
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood (2011) 1.76
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest (1989) 1.72
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol (2007) 1.41
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol (2008) 1.41
RMP, a novel RNA polymerase II subunit 5-interacting protein, counteracts transactivation by hepatitis B virus X protein. Mol Cell Biol (1998) 1.39
C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum (1992) 1.29
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells. Autophagy (2010) 1.27
URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell (2011) 1.25
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood (2001) 1.20
Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy (2011) 1.20
Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol (1999) 1.19
Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol (2008) 1.18
URI-1 is required for DNA stability in C. elegans. Development (2006) 1.16
A critical role for the NFkB pathway in multiple myeloma. Oncotarget (2010) 1.15
The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol (2007) 1.13
ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin Cancer Res (2010) 1.13
RPB5-mediating protein is required for the proliferation of hepatocellular carcinoma cells. J Biol Chem (2011) 1.03
Novel therapies for multiple myeloma. Br J Haematol (2003) 1.02
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant (2005) 1.00
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol (2000) 0.98
Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes. Cell Signal (2010) 0.96
Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer (2011) 0.95
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood (1996) 0.92
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood (2002) 0.87
Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J (2012) 0.87
Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther (2007) 0.83